Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

J. Grob,M. Amonkar,B. Karaszewska,J. Schachter,R. Dummer,A. Mackiewicz,D. Stroyakovskiy,K. Drucis,F. Grange,V. Chiarion-Sileni,P. Rutkowski,M. Lichinitser,E. Levchenko,P. Wolter,A. Hauschild
DOI: https://doi.org/10.1016/S1470-2045(15)00087-X
IF: 54.433
2015-10-01
The Lancet Oncology
Abstract:
What problem does this paper attempt to address?